Driving Change In Health Care

Jhaymee Tynan Talks About Patient Care In 2020 And Promoting Diversity

Jhaymee Tynan, assistant vice president of integration at Atrium Health and creator and founder of the 100x2030 Initiative, speaks to In Vivo about her journey into health care, putting the patient first, and the importance of encouraging diversity in the industry.

IV2008_Diversity-And-Healthcare_1200
'Diversity and inclusion will become part of how we do business and will be the foundation for how we move forward' • Source: Shutterstock

Jhaymee Tynan, one of In Vivo’s 2020 Rising Leaders, did not initially pursue a career in health care. After graduating from Virginia Tech with a bachelor’s degree in finance, insurance and business law, she aspired to work in banking. However, Tynan realized that while she enjoyed elements of the work, it did not offer her what she was looking for long-term. “I enjoyed working with people and solving problems, but I wanted a different lifestyle and work-life balance, and also wanted to be able to make an impact on people,” Tynan recalled in an exclusive interview.

At the same time, Tynan’s mother was dealing with health issues, and one particular visit spurred her to consider a...

More from Business Strategy

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.